Pureis and Cannaray have achieved a significant milestone as the first two CBD brands to have their novel food applications progressed beyond the risk assessment phase by the Food Standards Agency (FSA).
In an announcement this week, the FSA revealed that it has advanced the applications of both brands to the risk management stage, affirming that their CBD products are deemed safe for consumption when adhering to the recommended daily intake of up to 10mg.
Moving forward, the applications will undergo further scrutiny regarding various factors, including product labeling, which could potentially pose risks to consumers. Upon completion of this stage, they will be submitted for ministerial approval, paving the way for full authorization for sale.
Pureis and Cannaray distinguish themselves by utilizing synthetic 98% pure-form CBD and 98% pure-form CBD isolate, respectively, in their product lines, which include oils, drops, capsules, and gummies. Their products are available in leading retailers such as Holland & Barrett, Boots, and Amazon.
This advancement marks a significant milestone not only for Cannaray but for the entire CBD industry in the UK, according to Cannaray’s Managing Director, Howard Radcliffe. Radcliffe expressed pride in Cannaray’s commitment to excellence and compliance, positioning the brand at the forefront of innovation and setting industry standards.
Similarly, Pureis hailed the FSA’s decision as a groundbreaking moment, signaling a safer and more responsible era for CBD consumers in the UK. Chanelle McCoy, CEO of Pureis brand owner Chanelle McCoy Health, emphasized the monumental nature of this achievement and its transformative impact on the CBD industry.
While awaiting full regulatory approval, Chanelle McCoy Health is already contemplating new product development possibilities, incorporating CBD and other active ingredients into both oral and topical formulations. This strategic expansion aims to cater to consumers’ diverse needs and preferences while potentially creating new employment opportunities and fostering economic growth in the UK.
Despite the progress made, the FSA has not provided a definitive timeline for when brands and consumers can anticipate full authorization. Delays in this process prompted the Association for the Cannabinoid Industry (ACI) to voice concerns to FSA CEO Emily Miles, emphasizing the need for compliance with legal obligations regarding novel food applications.
